AP3170A - New CCR2 receptor antagonists and uses thereof - Google Patents

New CCR2 receptor antagonists and uses thereof

Info

Publication number
AP3170A
AP3170A AP2012006276A AP2012006276A AP3170A AP 3170 A AP3170 A AP 3170A AP 2012006276 A AP2012006276 A AP 2012006276A AP 2012006276 A AP2012006276 A AP 2012006276A AP 3170 A AP3170 A AP 3170A
Authority
AP
ARIPO
Prior art keywords
receptor antagonists
ccr2 receptor
new ccr2
new
antagonists
Prior art date
Application number
AP2012006276A
Other languages
English (en)
Other versions
AP2012006276A0 (en
Inventor
Kai Gerlach
Marco Santagostino
Christoph Hoenke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2012006276A0 publication Critical patent/AP2012006276A0/xx
Application granted granted Critical
Publication of AP3170A publication Critical patent/AP3170A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AP2012006276A 2009-12-17 2010-12-13 New CCR2 receptor antagonists and uses thereof AP3170A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09179555 2009-12-17
EP10162621 2010-05-12
PCT/EP2010/069549 WO2011073154A1 (en) 2009-12-17 2010-12-13 New ccr2 receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
AP2012006276A0 AP2012006276A0 (en) 2012-06-30
AP3170A true AP3170A (en) 2015-03-31

Family

ID=43533115

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006276A AP3170A (en) 2009-12-17 2010-12-13 New CCR2 receptor antagonists and uses thereof

Country Status (36)

Country Link
US (6) US8765949B2 (ja)
EP (3) EP2813503B1 (ja)
JP (1) JP5632014B2 (ja)
KR (1) KR101530234B1 (ja)
CN (1) CN102933579B (ja)
AP (1) AP3170A (ja)
AR (1) AR079636A1 (ja)
AU (1) AU2010332969B2 (ja)
BR (1) BR112012015873B1 (ja)
CA (1) CA2782464C (ja)
CL (1) CL2012001311A1 (ja)
CO (1) CO6650336A2 (ja)
CY (1) CY1115873T1 (ja)
DK (1) DK2513093T3 (ja)
EA (1) EA024397B1 (ja)
EC (1) ECSP12012010A (ja)
ES (2) ES2674275T3 (ja)
GE (1) GEP20146124B (ja)
HR (1) HRP20141143T1 (ja)
IL (1) IL219421A (ja)
MA (1) MA33818B1 (ja)
ME (1) ME01908B (ja)
MX (2) MX2012006964A (ja)
MY (1) MY160471A (ja)
NZ (1) NZ599770A (ja)
PE (1) PE20121614A1 (ja)
PH (1) PH12012501215A1 (ja)
PL (2) PL2513093T3 (ja)
PT (2) PT3091012T (ja)
RS (1) RS53555B1 (ja)
SG (1) SG181722A1 (ja)
SI (1) SI2513093T1 (ja)
TN (1) TN2012000300A1 (ja)
TW (1) TWI473800B (ja)
UY (1) UY33109A (ja)
WO (1) WO2011073154A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
ES2551557T3 (es) * 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2012171863A1 (en) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
JP5786258B2 (ja) * 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids
WO2016081801A1 (en) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Use of an anti-ccr2 antagonist in the treatment of an infectious disease
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
KR102444366B1 (ko) * 2016-06-03 2022-09-19 케모센트릭스, 인크. 간 섬유화 치료 방법
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
RU2768479C2 (ru) * 2016-06-13 2022-03-24 Хемоцентрикс, Инк. Способы лечения рака поджелудочной железы
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
US20210322412A1 (en) * 2020-04-20 2021-10-21 Centrexion Therapeutics Corporation Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) * 2020-10-20 2022-06-16 Lumicks Ca Holding B V Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US213428A (en) * 1879-03-18 Improvement in harrow-teeth
US568885A (en) * 1896-10-06 Can-seaming mechanism
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de) 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (ja) 1985-11-07 1988-06-01
JPS61165445A (ja) 1986-01-08 1986-07-26 株式会社巴組鐵工所 振動を減少しうる床構造
US5096916A (en) 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
AU678186B2 (en) 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629235A (en) 1995-07-05 1997-05-13 Winbond Electronics Corporation Method for forming damage-free buried contact
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
KR100607838B1 (ko) 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
EP1131318B1 (en) 1998-11-20 2004-03-24 G.D. Searle LLC Process for making 5-substituted pyrazoles using dithietanes
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SK286641B6 (sk) 1999-05-04 2009-03-05 Schering Corporation Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
DZ3347A1 (fr) 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
AU2002214996B2 (en) 2000-10-12 2007-03-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
CA2450961C (en) 2001-06-22 2010-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
PL372390A1 (en) 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
JP2003240776A (ja) 2002-02-13 2003-08-27 Horiba Ltd クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20050245537A1 (en) 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
JP3780291B2 (ja) 2002-04-29 2006-05-31 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤
TW200400960A (en) 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US20040147561A1 (en) 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2004074438A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
HRP20080541T3 (en) 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
ATE370135T1 (de) 2003-07-18 2007-09-15 Glaxo Group Ltd Substituierte piperidine als histamin-h3- rezeptorliganden
MXPA06001053A (es) 2003-07-29 2006-04-11 Novo Nordisk As Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3.
CA2550596C (en) 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
EP1753740A2 (en) 2004-05-21 2007-02-21 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
MEP8409A (en) 2004-06-02 2011-12-20 Fused heterocyclic compound
FR2871157A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Produits biaryl aromatiques, compositions les contenant et utilisation
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
ES2573845T3 (es) 2004-06-25 2016-06-10 Janssen Pharmaceutica Nv Antagonistas de CCR2 de sales cuaternarias
AU2005259983B2 (en) * 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN1976707A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
BRPI0517947A (pt) 2004-11-02 2008-10-21 Univ Northwestern composto de piridazina, composições e métodos
PA8653301A1 (es) 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
DE102004061751A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
BRPI0616575A2 (pt) 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053495A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20090062260A1 (en) 2005-11-14 2009-03-05 Irm Llc Compounds and compositions as lxr modulators
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
BRPI0620066A2 (pt) 2005-12-20 2011-11-01 Novartis Ag derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
IL172838A (en) 2005-12-27 2010-06-16 Joma Int As Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2465850B1 (en) 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
AU2007238878A1 (en) 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20100168120A1 (en) 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
GB0617575D0 (en) 2006-09-06 2006-10-18 Syngenta Ltd Herbicidal compounds and compositions
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
MX347085B (es) 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
FR2915552B1 (fr) 2007-04-27 2009-11-06 Technip France Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
RU2010103104A (ru) 2007-07-02 2011-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные имидазола в качестве антагонистов рецептора ccr2
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
EA017392B1 (ru) 2007-08-22 2012-12-28 Айрм Ллк Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
MX2010003621A (es) 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
WO2009047161A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
BRPI0816622A2 (pt) 2007-10-12 2015-03-10 Jong O Whang Dispositivo de amarrar cadarços que é fornecido sobre sapatos que possuem colchetes formados em posição oposta sobre os dois lados do peito do pé e dispositivo de amarrar cadarços que é fornecido sobre sapatos que posssuem colchetes formados em posição oposta sobre ambos os lados de sua parte interna
WO2009067406A1 (en) 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EP2225223B1 (de) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
CN102066359B (zh) 2008-06-18 2013-08-21 弗·哈夫曼-拉罗切有限公司 杂芳基甲酰胺衍生物
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2735208A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
CA2737645A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
ES2551557T3 (es) * 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
CA2750635A1 (en) 2009-02-23 2010-08-26 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
PL2513093T3 (pl) * 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
WO2011073155A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
JP6229575B2 (ja) 2014-03-31 2017-11-15 京セラドキュメントソリューションズ株式会社 画像処理装置
MX383744B (es) * 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.

Also Published As

Publication number Publication date
TN2012000300A1 (en) 2013-12-12
CA2782464A1 (en) 2011-06-23
US11046706B2 (en) 2021-06-29
HK1178147A1 (en) 2013-09-06
US10196402B2 (en) 2019-02-05
WO2011073154A1 (en) 2011-06-23
IL219421A0 (en) 2012-06-28
US8765949B2 (en) 2014-07-01
ES2524829T3 (es) 2014-12-12
JP5632014B2 (ja) 2014-11-26
RS53555B1 (sr) 2015-02-27
US12209094B2 (en) 2025-01-28
KR20120123652A (ko) 2012-11-09
AR079636A1 (es) 2012-02-08
EP3091012B1 (en) 2018-04-11
ES2674275T3 (es) 2018-06-28
PL2513093T3 (pl) 2015-03-31
EP2513093A1 (en) 2012-10-24
EA024397B1 (ru) 2016-09-30
CA2782464C (en) 2016-11-29
JP2013514301A (ja) 2013-04-25
EP2813503B1 (en) 2016-04-20
MX346393B (es) 2017-03-17
CO6650336A2 (es) 2013-04-15
TW201130816A (en) 2011-09-16
CN102933579A (zh) 2013-02-13
MY160471A (en) 2017-03-15
ME01908B (me) 2014-12-20
BR112012015873B1 (pt) 2021-06-01
AP2012006276A0 (en) 2012-06-30
DK2513093T3 (da) 2014-09-29
PT3091012T (pt) 2018-06-27
US20220002310A1 (en) 2022-01-06
CN102933579B (zh) 2015-07-15
AU2010332969A1 (en) 2012-05-31
EA201200876A1 (ru) 2013-01-30
TWI473800B (zh) 2015-02-21
ECSP12012010A (es) 2012-08-31
IL219421A (en) 2015-07-30
EP3091012A1 (en) 2016-11-09
US20190300541A1 (en) 2019-10-03
US11731981B2 (en) 2023-08-22
US20120004252A1 (en) 2012-01-05
PH12012501215A1 (en) 2015-11-13
BR112012015873A2 (pt) 2019-09-24
AU2010332969B2 (en) 2015-02-12
PE20121614A1 (es) 2012-12-21
US20140235661A1 (en) 2014-08-21
PL3091012T3 (pl) 2018-08-31
EP2813503A1 (en) 2014-12-17
SI2513093T1 (sl) 2014-11-28
HRP20141143T1 (hr) 2015-01-02
SG181722A1 (en) 2012-07-30
US9670222B2 (en) 2017-06-06
KR101530234B1 (ko) 2015-06-19
US20240109909A1 (en) 2024-04-04
MA33818B1 (fr) 2012-12-03
PT2513093E (pt) 2014-10-22
CY1115873T1 (el) 2017-01-25
EP2513093B1 (en) 2014-08-27
CL2012001311A1 (es) 2012-10-12
US20170362249A1 (en) 2017-12-21
GEP20146124B (en) 2014-07-25
UY33109A (es) 2011-07-29
NZ599770A (en) 2014-06-27
MX2012006964A (es) 2012-07-17

Similar Documents

Publication Publication Date Title
IL219421A0 (en) New ccr2 receptor antagonists and uses thereof
ZA201202029B (en) Androgen receptor antagonists and uses thereof
IL229507A0 (en) Extrinsic opioid receptor antagonists and their uses
ZA201203452B (en) Cgrp receptor antagonists
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
IL212436A0 (en) Isonicotinamide orexin receptor antagonists
IL218502A0 (en) Actriib antagonists and dosing and uses thereof
PL2927224T3 (pl) Antagoniści receptora
PL2137191T3 (pl) Antagoniści obwodowego receptora opioidowego i ich zastosowania
SG10201404662YA (en) Dp2 antagonist and uses thereof
HRP20150661T1 (en) Peripheral opioid receptor and antagonists and uses thereof
ZA200906812B (en) Crig antagonists
IL213250A0 (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
IL217965A0 (en) Bicyclic heterocycles and their use as ccr2 receptor antagonists
GB0701632D0 (en) MET receptor antagonists
GB0900754D0 (en) EP4 Receptor antagonists
GB0901836D0 (en) EP4 receptor antagonists
GB0900756D0 (en) EP4 Receptor antagonists
GB0900755D0 (en) Ep4 receptor antagonists
GB0705802D0 (en) Novel receptor antagonists and their methods of use
GB0709038D0 (en) Novel receptor antagonists and their methods of use